WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 55.64 CNY -1.43% Market Closed
Market Cap: 160.7B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi AppTec Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Total Liabilities & Equity
¥74.4B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Liabilities & Equity
¥23B
CAGR 3-Years
9%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Liabilities & Equity
¥56.1B
CAGR 3-Years
9%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Liabilities & Equity
¥30.4B
CAGR 3-Years
11%
CAGR 5-Years
37%
CAGR 10-Years
38%
Genscript Biotech Corp
HKEX:1548
Total Liabilities & Equity
$3.4B
CAGR 3-Years
22%
CAGR 5-Years
31%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Liabilities & Equity
¥6.7B
CAGR 3-Years
155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
162B CNY
Industry
Life Sciences Tools & Services

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
88.23 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
74.4B CNY

Based on the financial report for Sep 30, 2024, WuXi AppTec Co Ltd's Total Liabilities & Equity amounts to 74.4B CNY.

What is WuXi AppTec Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
22%

Over the last year, the Total Liabilities & Equity growth was 4%. The average annual Total Liabilities & Equity growth rates for WuXi AppTec Co Ltd have been 12% over the past three years , 22% over the past five years .

Back to Top